Solve ME
Non-Profit & Charitable Organizations · 11-50 Employees
View Company Info for Free
Overview
Website
www.solveme.orgRevenue
$18.5 MillionIndustry
About Solve ME
Solve ME Org Chart
Is Solve ME your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Solve ME has recently received funding, and reach out quickly before it becomes old news!
Click to see if Solve ME had a recent Job posting/layoffs
Solve ME, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Solve ME
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Solve ME has new funding data
Earning: See what the market has to say on Solve ME recently announced quarterly report
Check out if Solve ME is spiking on competitors!
Product Launch: Get notified when Solve ME launches new products
Recommended Actions
Reach out to Masked Content who joined Solve ME as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Solve ME is experiencing very low activity levels compared to other companies in the Organizations sector.
What does this means?
Solve ME is drawing exceptional interest within the Organizations industry, suggesting notable developments or strong market momentum, learn more about Solve ME.
Solve ME Tech Stack
A closer look at the technologies used by Solve ME
Most Recent Scoops
Solve ME News & Media
Solve M.E. Funds GLP-1 and Immune Target Studies to Accelerate ME/CFS and Long Covid Breakthroughs
The Solve ME/CFS Catalyst Award-winning studies will fast-track clinical and immunological studies aimed at delivering new treatment strategies and diagnostic insights for ME/CFS and Long Covid, conditions still lacking FDA-approved therapies. LOS ANGELES, Feb. 24, 2026 /PRNewswire/ --...Solve M.E. Selects Simmaron Research As Recipient of ME/CFS Catalyst Award to Accelerate Low-Dose Rapamycin Trial for ME/CFS, Long COVID, and IACCs
The Catalyst Award will expedite the hunt for a validated test-to-treat model for ME/CFS, a disease for which there is currently no FDA-approved treatment. LOS ANGELES, June 17, 2025 /PRNewswire/ -- Solve M.E. is proud to announce the second recipient of its 2025 ME/CFS Catalyst Award:...Trailblazing Researcher Receives Inaugural ME/CFS Catalyst Award from Solve M.E.
New Catalyst Award funds high-impact research by Dr. Akiko Iwasaki, accelerating breakthroughs for millions. LOS ANGELES, May 12, 2025 /PRNewswire/ -- In recognition of World ME Day (May 12) and its commitment to advancing urgently needed biomedical research, Solve M.E. is proud to...Solve M.E., Brain Inflammation Collaborative (BIC), ChronicleBio, Complex Disorders Alliance, and CareEvolution Launch Groundbreaking Partnership to Accelerate Research on ME/CFS, Long Covid, and IACCIs
LOS ANGELES, April 29, 2025 /PRNewswire/ -- Solve M.E., the Brain Inflammation Collaborative (BIC), ChronicleBio, the Complex Disorders Alliance, and CareEvolution have launched a powerful new collaboration to advance research on myalgic encephalomyelitis (ME)/chronic fatigue syndrome...
Top Non-Profit & Charitable Organizations Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Solve ME
Solve M.E. is a non-profit organization that serves as a catalyst for critical research into diagnostics, treatments, and cures for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), Long Covid, and other post-infection diseases. Our work with the scientific, medical, and pharmaceutical communities, advocacy with government agencies, and... Read More